SIBLINGs and SPARC families: Their emerging roles in pancreatic cancer

作者: Ferda Kaleağasıoğlu , Martin R Berger

DOI: 10.3748/WJG.V20.I40.14747

关键词:

摘要: Pancreatic cancer has a considerably poor prognosis with 5-year survival probability of less than 5% when all stages are combined. is characterized by its dense stroma, which involved in the critical interplay tumor cells throughout progression and furthermore, creates barrier restricting efficient penetration therapeutics. Alterations large number genes reflected limited signaling pathways, potential targets. Understanding more about molecular basis this devastating type regarding microenvironment, distinct subpopulations cells, epithelial-to-mesenchymal transition inflammation will lead to development various targeted therapies for controlling growth metastasis. In complex scenario pancreatic cancer, especially members “small integrin binding ligand N-linked glycoproteins” (SIBLINGs) “secreted protein acidic rich cysteine” (SPARC) families have emerged due their prominent roles properties including proliferation, differentiation, apoptosis, adhesion, migration, angiogenesis, wound repair regulation extracellular matrix remodeling. SIBLINGs consist five members, include osteopontin (OPN), bone sialoprotein, dentin 1, sialophosphoprotein phosphoglycoprotein. The SPARC family modular proteins comprised SPARC/osteonectin (ON) SPARC-like 1 (hevin); secreted calcium proteins; testicans follistatin-like protein. review, we focus on OPN ON, elaborating special growing importance diagnosis prognosis.

参考文章(113)
Christine A. Iacobuzio-Donahue, Byungwoo Ryu, Ralph H. Hruban, Scott E. Kern, Exploring the Host Desmoplastic Response to Pancreatic Carcinoma: Gene Expression of Stromal and Neoplastic Cells at the Site of Primary Invasion American Journal of Pathology. ,vol. 160, pp. 91- 99 ,(2002) , 10.1016/S0002-9440(10)64353-2
Karl-Hermann Schlingensiepen, Birgit Fischer-Blass, Susanne Schmaus, Sylvia Ludwig, Antisense Therapeutics for Tumor Treatment: The TGF-beta2 Inhibitor AP 12009 in Clinical Development Against Malignant Tumors Pancreatic Cancer. ,vol. 177, pp. 137- 150 ,(2008) , 10.1007/978-3-540-71279-4_16
Katherine E. Poruk, Matthew A. Firpo, Courtney L. Scaife, Douglas G. Adler, Lyska L. Emerson, Kenneth M. Boucher, Sean J. Mulvihill, Serum Osteopontin and Tissue Inhibitor of Metalloproteinase 1 as Diagnostic and Prognostic Biomarkers for Pancreatic Adenocarcinoma Pancreas. ,vol. 42, pp. 193- 197 ,(2013) , 10.1097/MPA.0B013E31825E354D
Deric L. Wheeler, Toni M. Brand, Mari Iida, Chunrong Li, The nuclear epidermal growth factor receptor signaling network and its role in cancer Discovery Medicine. ,vol. 12, pp. 419- 432 ,(2011)
Konstantinos N Syrigos, Georgios Michael Oikonomopoulos, Muhammad Wasif Saif, Prognostic Factors in Pancreatic Cancer Journal of the Pancreas. ,vol. 14, pp. 322- 324 ,(2013) , 10.6092/1590-8577/1644
Sandra A. Rempel, William A. Golembieski, James L. Fisher, Michael Maile, Alexander Nakeff, SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. Journal of Neuro-oncology. ,vol. 53, pp. 149- 160 ,(2001) , 10.1023/A:1012201300188
A Claeskens, N Ongenae, J M Neefs, P Cheyns, P Kaijen, M Cools, E Kutoh, Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. British Journal of Cancer. ,vol. 82, pp. 1123- 1130 ,(2000) , 10.1054/BJOC.1999.1051
E. J. Manseau, B. Berse, A. Papadopoulos-Sergiou, K. Tognazzi, C. A. Perruzzi, L. F. Brown, H. F. Dvorak, D. R. Senger, Osteopontin expression and distribution in human carcinomas. American Journal of Pathology. ,vol. 145, pp. 610- 623 ,(1994)
J. E. Schnitzer, P. Oh, Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium American Journal of Physiology-heart and Circulatory Physiology. ,vol. 263, ,(1992) , 10.1152/AJPHEART.1992.263.6.H1872
Ralph H. Hruban, Neal S. Fedarko, Anirban Maitra, Jens Koopmann, Charles J. Yeo, Alka Jain, Ayman Rahman, Michael Goggins, Christine Iacobuzio-Donahue, Evaluation of Osteopontin as Biomarker for Pancreatic Adenocarcinoma Cancer Epidemiology, Biomarkers & Prevention. ,vol. 13, pp. 487- 491 ,(2004)